Global Hepatitis Drugs Market
Hepatitis B is a viral infection that affects the liver and subsequently leads to acute, chronic liver disorders. According to the World Health Organization (WHO) 2018, it is estimated that about 780,000 people die each year due to complications of hepatitis B, such as liver cirrhosis and liver cancer. Hepatitis B virus (HBV) is highly contagious, and is transmitted through contact with the blood or other body fluids of an infected person.
The global hepatitis drugs market was assessed at US$ 21,148.3 million in 2019, and is expected to witness a CAGR of 3.2% over the forecast period (2019-2027).
Get Sample R&D PDF of Hepatitis Drugs Market: https://www.coherentmarketinsights.com/insight/request-sample/2977
Leading Players
The key players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Launch of new drugs and increasing regulatory approvals for hepatitis drugs is expected to drive the growth of the global hepatitis drug market
Increasing approvals for hepatitis drugs from regulatory authorities is expected to drive the global hepatitis drugs market growth during the forecast period. For instance, in 2016, the U.S. FDA approved the Elbasvir drug for the treatment of hepatitis C, Elbasvir is a highly potent and selective NS5A inhibitor of the hepatitis C virus NS5A replication complex.
Launch of new drugs for hepatitis treatment is expected to drive growth of the hepatitis drugs market over the forecast period. For instance, in 2018, Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.
Browse Press Release: https://bit.ly/2SJDlu4
Global Hepatitis Drugs Market Restraints
The high capital investments required for the manufacture of hepatitis drugs is a significant aspect likely to hamper the growth of the global hepatitis drugs market over the forecast period. Hepatitis drugs are costly as the manufacturing process requires expensive raw materials, such as active pharmaceutical ingredients (APIs) and drug intermediates. The production, isolation, and usage of raw materials for pharmaceutical and biopharmaceutical drug production, is a complex process and requires a skilled workforce, which adds to the overall costs of pharmaceuticals.
Global Hepatitis Drugs Market – Regional Insights
North America is expected to hold a dominant position in the global hepatitis drugs market in the near future, owing to the increasing government initiatives being taken for the prevention of HBV infections. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the US. The plan outlines strategies to achieve four major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths and improving the health of people with viral hepatitis.
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2977
Asia Pacific is foreseen to observe rapid growth in the global hepatitis drugs market over the forecast timeframe, owing to rising demand for generic drugs in this region. For instance, in 2015, Gilead licensed its hepatitis C drug, called Sovaldi, to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.
Detailed Segmentation:
- Global Hepatitis Drugs Market, By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
- Global Hepatitis Drugs Market, By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
- Global Hepatitis Drugs Market, By Route of Administration:
- Oral
- Injection
- Global Hepatitis Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: : sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
